HEALTHJun 30 · 08:05 UTCCNBC TOP

French biotech stock soars 31% after new data on experimental medicine

Shares of French biotech company Abivax rose 31% after releasing new data on its lead drug for bowel disease.

Nexus surfaces and summarizes. The full story lives at the source.

Mentioned

AbivaxorganizationFranceplacebowel diseasetopic

Spot something wrong with this article?Report a problem →

Forward this

Related Signal

Adjacent reporting

HEALTHJun 2 · 07:43 UTC
Biotech takeover target Abivax sinks over 30% after bowel disease drug trial update
BUSINESSApr 17 · 17:41 UTC
Obesity Firm Kailera Therapeutics Up 63% After $625 Million IPO
BUSINESSJun 3 · 13:36 UTC
STAT+: Legend Biotech emerged as a rare market winner
BUSINESSJun 3 · 04:14 UTC
Chinese biotech GenScript surges as it rebuffs US lawmakers’ allegations
BUSINESSJun 10 · 16:21 UTC
Cancer drug startup Parabilis Medicines is raising a record $670 million in its IPO
HEALTHJun 30 · 07:05 UTC
STAT+: Abivax seeks to ease safety concerns with new data, boosting shares